CN115813972B - Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof - Google Patents
Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof Download PDFInfo
- Publication number
- CN115813972B CN115813972B CN202211166878.3A CN202211166878A CN115813972B CN 115813972 B CN115813972 B CN 115813972B CN 202211166878 A CN202211166878 A CN 202211166878A CN 115813972 B CN115813972 B CN 115813972B
- Authority
- CN
- China
- Prior art keywords
- medicine
- ischemic stroke
- parts
- zhuang
- acute stage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a Zhuang medicine compound medicine for treating ischemic stroke in an acute stage, which comprises the following raw materials in parts by weight: 30-40 parts of earthworm, 30-40 parts of suberect spatholobus stem and 30-40 parts of szechuan lovage rhizome. The invention also discloses a preparation method of the Zhuang medicine compound medicine for treating ischemic stroke in the acute stage, which comprises the following steps: (1) soaking the raw materials in water; and (2) after the soaking is finished, carrying out concentrated decoction to obtain the liquid medicine. The invention improves the symptoms of ischemic cerebral apoplexy patients by dredging the toxic evil stasis of the dragon way and the fire way, has simple prescription and good curative effect, overcomes the defects of large side effect and easy drug resistance of western medicines, and develops the advantages of small side effect and difficult drug resistance of traditional Chinese medicines.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine formulas, and in particular relates to a Zhuang medicine compound medicine for treating ischemic stroke in an acute stage and a preparation method thereof.
Background
Acute ischemic cerebral apoplexy (AcuteIschemicStroke, AIS) accounts for 43% -65% of all cerebrovascular diseases, and is one of common cerebrovascular diseases. The incidence of AIS has the characteristics of high disability rate and high recurrence rate, and the main mechanism is caused by the damage of nerve blood vessels of brain tissues in ischemic areas due to the blockage of main arteries supplying brain blood and the reduction of blood flow perfusion of brain tissues. Factors such as hypertension, diabetes and arteriosclerosis can induce AIS, promote cerebral thrombosis, and thus cause ischemia reperfusion injury, and accelerate formation of brain tissue edema.
Acute ischemic stroke is a major fatal, disabling disease worldwide, with millions of people being involved each year. Although great progress has been made in the treatment of cerebral infarction in recent years, intravenous application of tissue-type plasminogen activator (tissue pLasminogenactivator tPA) and intravascular thrombus removal (endovascuLar thrombectomv) remain the standard treatments for treating acute ischemic stroke. Although the use of intravenous tPA and intravascular thrombectomy greatly increases the recanalization rate of occluded blood vessels, more than half of patients still fail to achieve effective tissue reperfusion and improved clinical prognosis. The mechanism is very complex and is not completely clear at present. There is growing evidence that thrombus formation in microvasculature downstream of the occluded cerebral vessels is involved in mediating the formation of such ineffective recanalization (with or without recanalization). Furthermore, inflammatory cells also affect the formation of these thrombi, and the two processes of inflammatory reaction and thrombosis interweave with each other to mediate microthrombosis formation after AIS.
Although various expert scholars have made a great deal of research on the pathogenesis of ischemic cerebral apoplexy, the pathogenesis of the cerebral arterial thrombosis is still not clear and is on a perfect road. Because of the complexity of the etiology and pathogenesis of the ischemic cerebral apoplexy, the causative cause of clinical patients is often uncertain, and in the aspect of western medicine treatment, the treatment measures are difficult to be carried out aiming at the etiology, and only symptomatic treatment can be carried out.
In the aspect of traditional Chinese medicine treatment:
chinese patent CN110613758A discloses a Chinese medicinal composition for treating ischemic apoplexy, which is prepared from radix astragali, radix Acanthopanacis Senticosi, caulis Spatholobi, rhizoma Ligustici Chuanxiong, herba Lycopodii, fructus crataegi, eupolyphaga Seu Steleophaga, zaocys, fructus Chaenomelis, scolopendra, lumbricus and Hirudo. In the formula, astragalus root is a monarch drug for greatly reinforcing spleen and stomach middle-jiao qi to nourish the source, and acanthopanax root is used for reinforcing spleen and lung qi; the raw hawthorn can remove food retention and remove blood stasis, harmonize stomach and invigorate spleen, and assist astragalus root to replenish qi as ministerial drug. The Ligusticum wallichii, the caulis spatholobi, the ground beetle, the leech and the zaocys dhumnade are added, the earthworm, the centipede, the ground beetle, the leech and the zaocys dhumnade are added, and the earthworm calms wind and relieves spasm; the centipede has the highest channeling force; ground beetle enters blood, softens hard mass and removes blood stasis; leech, which is fond of eating blood of people, is slow in nature and enters, zaocys is good at moving, and is combined with Huang Qi to strengthen the actions of tonifying qi and dredging collaterals. Chuan Chaenomeles speciosa is also dedicated to liver, benefit tendons and blood; herba Lycopodii has the effects of relaxing tendons and activating collaterals, and the two are combined together to form the combined preparation. The medicines are combined together, so that qi is high, blood circulation is achieved, blood stasis is removed, collaterals are removed, muscles and tendons are nourished, and the flaccidity and disability are recovered.
Chinese patent CN102648961B discloses a medicament for treating ischemic stroke sequela, which is prepared from traditional Chinese medicines such as red sage root, chinese angelica, szechuan lovage rhizome, saffron, cassia twig, garden balsam stem, tetrandra root, nux vomica, eucommia bark, large-leaved gentian, suberect spatholobus stem, dahurian angelica root, common monkshood mother root, kusnezoff monkshood root, dahurian angelica root, common floweringquince fruit, sanguinea, musk, borneol, radix achyranthis bidentatae, earthworm, pangolin scales, leech, platycodon root, liquorice, sanguinea brown, arisaema cum bile, astragalus root and the like by soaking and heating.
Chinese patent CN101310737B discloses a medicament for treating ischemic stroke, which is mainly prepared from radix salviae miltiorrhizae, radix astragali, caulis spatholobi, chinese angelica, safflower, szechuan lovage rhizome, red paeony root, leech, ground beetle, earthworm, zaocys dhumnade and pseudo-ginseng according to a certain weight ratio. The prescription has the effects of removing blood stasis, dredging collaterals, invigorating qi and promoting blood circulation.
Chinese patent CN1272039C discloses a Chinese patent medicine for treating apoplexy and a preparation method thereof, and the Chinese patent medicine is mainly prepared from astragalus, spatholobus stem, angelica, ligusticum wallichii, earthworm, leech, stiff silkworm, scorpion, uncaria and other medicinal materials into a required dosage form; the Chinese patent medicine preparation has the effects of tonifying qi and nourishing blood, dispelling wind and resolving phlegm, and promoting blood circulation and removing obstruction in collaterals, is mainly suitable for patients with qi deficiency and blood stasis syndrome and wind phlegm and blood stasis obstruction of collaterals syndrome seen in channels and collaterals in (ischemic) apoplexy, and is especially suitable for patients in recovery period.
The medicine formulas of the 4 patents all contain a plurality of medicine components, are complex, and have high cost, and report new medicines.
Chinese patent CN113713010A discloses a formula for treating acute ischemic stroke by strengthening yang, which is prepared from raw material medicaments of strengthening yang and compatible medicinal materials. The compatibility medicine is ramulus Cinnamomi-rhizoma Ligustici Chuanxiong, ramulus Cinnamomi-radix Angelicae sinensis, ramulus Cinnamomi-Lumbricus, ramulus Cinnamomi-radix astragali, ramulus Cinnamomi-radix Angelicae sinensis, ramulus Cinnamomi-radix Paeoniae Rubra, ramulus Cinnamomi-semen Persicae, ramulus Cinnamomi-Carthami flos, and ramulus Cinnamomi-Saviae Miltiorrhizae radix. The prescription has simple components and is mainly used for treating acute ischemic stroke by strengthening yang.
Dragon and fire are the names of two extremely important internal closed passages for maintaining the vitality of human body and reflecting the disease dynamics although the interior of the human body is not directly communicated with the nature by Zhuang medical science. The Zhuang nationality traditional considers that the dragon is made into water, namely the dragon way is a blood channel in the human body (so some strong doctors are also called blood vessels and dragon veins), and the function of the dragon way is mainly to convey nutrition to viscera, bones and meat. The dragon road has a trunk line, a network, and circulation throughout the whole body, wherein the dragon road is pivoted in the heart. Fire is the trigger, its nature is rapid ("rapid fire" means) and the sense of burning. The strong doctor considers that the fire path is a sensing path in the human body, and can also be called as an information channel in modern language. Which is centered in a "smart dock". The fire path is the same as the dragon path, has a trunk line and a network, and extends over the whole body, so that a normal human body can feel various information and stimulation from the outside in a very short time, and rapidly responds through the treatment of a central 'smart dock', thereby adapting to various changes from the outside and realizing physiological balance of 'three-qi synchronization'. When the fire is blocked, the human body loses the response and adaptation ability to the external information, and the disease and even death are caused.
Disclosure of Invention
The invention aims to provide a Zhuang medicine compound medicine for treating ischemic stroke in an acute stage, which improves symptoms of ischemic stroke patients by dredging toxic evil stasis of dragon ways and fire ways, has simple prescription and good curative effect, overcomes the defects of large side effect and easy drug resistance of western medicines, and develops the advantages of small side effect and difficult drug resistance of traditional Chinese medicines.
A Zhuang medicine compound medicine for treating ischemic stroke in the acute stage comprises the following raw materials in parts by weight: 30-40 parts of earthworm, 30-40 parts of suberect spatholobus stem and 30-40 parts of szechuan lovage rhizome.
Further, the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following raw materials in parts by weight: 30 parts of earthworm, 40 parts of suberect spatholobus stem and 30 parts of szechuan lovage rhizome.
Further, the preparation method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps:
(1) Soaking the raw materials in water;
(2) And after the soaking is finished, carrying out concentrated decoction to obtain the liquid medicine.
Further, the using method comprises the following steps: after the raw materials are prepared into liquid medicine, 150mL of the liquid medicine is taken after 2 times of meals in the morning and evening.
Further, 8 weeks is a treatment course.
Further, in the step (1), the feed-liquid ratio is 1:6.
Further, in the step (1), the soaking time is 30-60 min.
In the step (2), the decoction time is 30-40 min.
Further, in the step (2), the volume of the obtained liquid medicine is 150-170 mL.
The sources and effects of the raw materials of the invention are as follows:
earthworm: pheretima, silkworm, earum japonicum, pheretima, and Eupolyphaga Seu Steleophaga. Cold in nature and salty in taste, enter liver, stomach, lung and bladder meridians. The functions are as follows: clearing heat, suppressing hyperactive liver, relieving asthma, and dredging collaterals. Headache due to wind-heat, conjunctival congestion, hemiplegia, etc. The main indications are: hemoptysis, hematemesis, epistaxis, hematochezia, metrorrhagia, traumatic hemorrhage, thoracoabdominal pain, traumatic swelling and pain, and can be used for treating hyperpyrexia, coma, convulsion, arthralgia, cough due to lung heat, edema due to oliguria, hypertension, etc.
Caulis Spatholobi: is dried rattan of Sparassis crispa SpathoLobus suberectus Dunn of Leguminosae. Bitter and sweet in taste and warm in temperature; it enters liver and kidney meridians. Efficacy: promoting blood circulation, replenishing blood, regulating menstruation, relieving pain, relaxing tendons, and activating collaterals. The main indications are: it can be used for treating menoxenia, dysmenorrhea, amenorrhea, rheumatalgia, numbness, paralysis, and sallow complexion due to blood deficiency.
Ligusticum wallichii: the academic name Ligusticum chuanxiong hort. The aliases mountain cui, xiong tip, bergamot fruit, hu, sparrow brain, jingxiong, chun, raw rhubarb. Pungent and warm in flavor. Enter gallbladder and liver meridian. Efficacy: promoting qi circulation, resolving stagnation, dispelling pathogenic wind, removing dampness, promoting blood circulation, and relieving pain. The main indications are: menoxenia, amenorrhea dysmenorrhea, abdominal pain, chest and hypochondrium stabbing pain, traumatic injury, headache, rheumatalgia and the like.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention starts from dredging the toxic evil stasis of the dragon road and the fire road, is prepared by using the Zhuang medicine components with unique curative effect, has the advantages of small side effect and difficult generation of drug resistance, overcomes the defects of large side effect and easy generation of drug resistance of western medicines, and has the characteristics of wide source, low cost, convenient use and obvious curative effect, and the preparation process is simple.
2. The compound prescription of the invention can dredge the long way and the fire way for toxin and evil stasis. And only 3 medicines are adopted for compatibility, the medicine is obtained by screening and simplifying experiments of comparing effects with a plurality of medicines, the medicine formula is greatly simplified, medicine resources are saved, meanwhile, the complexity of reporting new medicines is simplified, the symptoms of patients suffering from ischemic cerebral apoplexy can be improved, and the curative effect is obvious, exact and stable, and has no toxic or side effect.
3. The compound medicine of the invention only uses 3 medicines of earthworm, suberect spatholobus stem and szechuan lovage rhizome, wherein the earthworm has the effects of clearing heat and arresting convulsion, reducing blood pressure, promoting the circulation of qi and relieving the obstruction of the channels; caulis Spatholobi has effects of promoting blood circulation, replenishing blood, relieving rigidity of muscles, activating collaterals, promoting blood circulation, dredging and tonifying; ligusticum wallichii has the effects of promoting qi circulation, dispelling wind, eliminating dampness, promoting blood circulation, relieving pain, and promoting the circulation of qi and blood; the combination of the three components can dredge the dragon way on one hand, so that the blockage situation of main arteries supplying cerebral blood for patients with ischemic cerebral apoplexy can be effectively improved, and the blood flow perfusion quantity of cerebral tissues can be increased; on the other hand, the toxic evil stasis of the fire path is dredged, and the influence of inflammatory reaction is reduced, so that the nerve blood vessel of brain tissue in an ischemic area is protected from being damaged.
Detailed Description
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Example 1
A Zhuang medicine compound medicine for treating ischemic stroke in the acute stage comprises the following raw materials in parts by weight: 30g of earthworm, 30g of suberect spatholobus stem and 40g of szechuan lovage rhizome.
The preparation method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps:
(1) Cleaning all the raw materials, filtering to remove impurities, and adding 600mL of water for 30min;
(2) After the soaking is finished, the mixture is decocted for 30min to obtain 170mL of liquid medicine.
The application method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps: taking 150mL of the medicine liquid, and taking the medicine liquid warm after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
Example 2
A Zhuang medicine compound medicine for treating ischemic stroke in the acute stage comprises the following raw materials in parts by weight: 40g of earthworm, 30g of suberect spatholobus stem and 30g of szechuan lovage rhizome.
The preparation method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps:
(1) Cleaning all the raw materials, filtering to remove impurities, and adding 600mL of water for soaking for 50min;
(2) After the soaking is finished, the mixture is decocted for 35min to obtain 160mL of liquid medicine.
The application method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps: taking 150mL of the medicine liquid, and taking the medicine liquid warm after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
Example 3
A Zhuang medicine compound medicine for treating ischemic stroke in the acute stage comprises the following raw materials in parts by weight: 30g of earthworm, 40g of suberect spatholobus stem and 30g of szechuan lovage rhizome.
The preparation method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps:
(1) Cleaning all the raw materials, filtering to remove impurities, and adding 600mL of water for 60min;
(2) After the soaking is finished, the mixture is decocted for 40min to obtain 150mL of liquid medicine.
The application method of the Zhuang medicine compound medicine for treating the acute stage of ischemic stroke comprises the following steps: taken after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
Comparative example 1
Raw materials: 100g of earthworm.
The preparation method comprises the following steps:
(1) Cleaning, filtering to remove impurities, and soaking in 600mL water for 60min;
(2) After soaking, decocting for 40min to obtain 150mL of liquid medicine;
the using method comprises the following steps: taken after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
Comparative example 2
Raw materials: 100g of spatholobus stem.
The preparation method comprises the following steps:
(1) Cleaning, filtering to remove impurities, and soaking in 600mL water for 60min;
(2) After soaking, decocting for 40min to obtain 150mL of liquid medicine;
the using method comprises the following steps: taken after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
Comparative example 3
Raw materials: ligusticum wallichii 100g.
The preparation method comprises the following steps:
(1) Cleaning, filtering to remove impurities, and soaking in 600mL water for 60min;
(2) After soaking, decocting for 40min to obtain 150mL of liquid medicine;
the using method comprises the following steps: taken after 2 times of meals in the morning and evening; 8 weeks as a treatment course.
1. Animal experiment
1. Experimental materials
Experimental animals and feeding: healthy male SPF grade SD rats 90, 250±50g body weight, animal license number 430727211101291332, experimental animal license number: SC XK (Hunan) 2019-0004. All experimental procedures were approved by the university of Guangxi Chinese medicine ethics Committee (DW 20200415-53). Feeding conditions: the room temperature is between 22 and 24 ℃, the humidity is between 40 and 70 percent, the lighting time of light and dark alternation is 12 hours, and the food intake by free drinking water is realized.
MCAO/R model preparation: rat MCAO/R model is prepared by Longa line suppository method, 10% of 10 mL/kg is injected into abdominal cavity -1 The method comprises the steps of conducting anesthesia on rats through chloral hydrate, longitudinally cutting skin on the middle of the neck, blunt separating subcutaneous glands and tissues of the neck, separating right common carotid artery, threading on the proximal end of the common carotid artery, separating the external carotid artery and the internal carotid artery upwards from the bifurcation of the common carotid artery, ligating the proximal end of the common carotid artery and the proximal end of the external carotid artery, preparing wires under the residual carotid artery, temporarily clamping the internal carotid artery by using a small-sized arterial clamp, cutting a small opening on the residual carotid artery by using ophthalmic scissors, pulling the ligature of the residual carotid artery, enabling the residual carotid artery to be consistent with the internal carotid artery in direction, inserting the ball end of a wire plug into the internal carotid artery, enabling the ball end of the wire plug to enter 2cm, moderately ligating the neck skin by using the prepared wires, pulling out the wire plug after 2h, manufacturing an MCAO/R model, and observing whether cerebral infarction is caused by using TTC staining to see whether a model is successful or not.
3. Drug administration and sampling test: rats were randomly divided into a control group, a model group, a sham operation group, and 6 drug solution groups, each group having 10 animals.
Control group: normal feeding, free drinking, and filling with equal volumes of normal saline, 1 time each day in the morning and afternoon;
model group: establishing a rat MCAO/R model, normal feeding after modeling, free drinking water, and filling with equal volume of physiological saline, 1 time each day in the morning and afternoon;
group of sham operations: the operation steps are the same as the model group, arteries are not ligated, after the operation, animals are awake, normal feeding, free drinking water and gastric lavage of equal volumes of physiological saline are carried out, and each time is 1 day in the morning and afternoon;
drug group: the MCAO/R model of the rat is built, and the liquid medicines of examples 1-3 and comparative examples 1-3 are respectively infused into the rat 1h after the anesthesia and the waking, wherein the gastric infusion dose is 1.4mL/100g of the rat each time, and 1 time is respectively carried out on the day and the afternoon.
Neurological dysfunction score: neurological dysfunction was scored 24h after dosing was completed.
Cerebral infarction volume measurement: after 3d administration, the rat was sacrificed after head breaking, and brain tissue was rapidly removed to remove olfactory bulb, cerebellum and low brain stem, and frozen at-20℃for 10min. From the anterior electrode (anticoropol e) 1mm thick brain coronal sections were cut continuously, and 2% 2,3,5-triphenyltetrazolium chloride (TTC, available from sigma) in a physiological saline solution were incubated at 37℃for 10min in the absence of light and 10% formaldehyde neutral buffer (pH 7.4) was fixed overnight. The macro camera shoots, and Image pro plus 6.0 Image analysis software calculates and counts cerebral infarction volumes, and the results are shown in table 2.
4. Experimental results
4.1 neurological dysfunction score: each group of rats was scored for neuromotor dysfunction according to a scoring criteria for pentad: score 0, normal, no neurological signs; 1 min, the left forelimb cannot be fully extended; 2 minutes, the left side turns when walking; 3 minutes, the left side of the walking chair tilts when walking; 4 minutes, no autonomous walking is carried out and the consciousness level is reduced; 5 minutes, death. The results are shown in Table 1.
TABLE 1 rat neurological dysfunction scoring results
| Group of | Score of |
| Control group | 0 |
| Model group | 4.4 |
| False operation group | 3.8 |
| Example 1 | 2.5 |
| Example 2 | 2.3 |
| Example 3 | 2.2 |
| Comparative example 1 | 3.9 |
| Comparative example 2 | 3.8 |
| Comparative example 3 | 4.1 |
From the above table, the left forelimb on the opposite side of the injury can not be stretched, the left forelimb turns or falls down during walking, and even the rats can not walk autonomously, the consciousness level is reduced or the obvious ischemic cerebral apoplexy nerve dysfunction symptoms such as death can not be caused after the operation of the rats in the model group. The earthworm, the suberect spatholobus stem and the ligusticum wallichii have the protection effect on the nerve dysfunction caused by the transient cerebral ischemia of the rats, and the protection effect is enhanced when the earthworm, the suberect spatholobus stem and the ligusticum wallichii are mixed, wherein the protection effect of the embodiment 3 is the strongest. The compound medicine of earthworm, suberect spatholobus stem and szechuan lovage rhizome has the function of relieving nerve dysfunction caused by transient cerebral ischemia of rats and has better protection effect on ischemic cerebral apoplexy nerve injury.
TABLE 2 calculation of cerebral infarction volumes of rats
As shown in the table above, the earthworms, the suberect spatholobus stems and the ligusticum wallichii have the effect of reducing the cerebral infarction volume of rats to a certain extent, and the protection effect is enhanced when the earthworms, the suberect spatholobus stems and the ligusticum wallichii are mixed, wherein the protection effect of the embodiment 3 is strongest.
2. Clinical study
1. Medical record data
1.1 selecting the number of people
120 patients with ischemic stroke were selected.
1.2 diagnostic criteria
And the method is implemented by referring to the disease diagnosis standard in the stroke diagnosis and curative effect evaluation standard formulated by the national medical administration medical administration encephalopathy emergency cooperation group.
Stroke diagnosis criteria:
(1) Main symptoms are as follows: hemiplegia, mental confusion, slurred speech or no speech, abnormal body deviation and feeling, facial distortion;
(2) Secondary symptoms: headache, dizziness, pupil-mind changes, choking when drinking water, and ataxia;
(3) The onset mode is as follows: acute onset usually has predisposition before onset, often has premonitory symptoms;
(4) Age of onset: most often over 40 years old.
The diagnosis can be confirmed by combining more than 2 main symptoms or 1 main symptoms and 2 secondary symptoms, with diseases, causes, premonitory symptoms and ages and then combining imaging examination results.
1.3 case inclusion criteria
(1) Meets the diagnosis standard of traditional Chinese and western medicine for ischemic stroke;
(2) The age is 45-75 years old;
(3) Chinese patent medicine, decoction or related western medicines for treating apoplexy are not used after the onset of the disease;
(4) Each patient group was approved by the ethical committee of the hospital and had to sign informed consent.
1.4 case exclusion criteria
Except for one of the following cases:
(1)TIA；
(2) Bleeding converters after cerebral infarction;
(3) Cerebral embolism caused by brain trauma, intracranial tumor, cerebral endoparasitis, atrial fibrillation, etc.;
(4) Allergic constitution;
(5) Combining primary diseases such as liver, kidney, metabolic system and blood system, and the like, and is difficult for a person to evaluate the safety of research;
(6) Patients with mental diseases can not express the mental diseases accurately.
1.5 reject and drop criteria
(1) Cases that do not meet inclusion criteria or are misentered;
(2) The subject's condition does not reach the desired degree of control over a period of time;
(3) Affecting the curative effect judgment, if the medicine is not used according to the specification or the clinical data is not complete;
(4) For various reasons, the subject is self-requesting to withdraw from the test;
(5) Serious other concurrent disease patients appear in the research process;
(6) Other medications that may affect efficacy assessment were taken during the study.
2. Method of
2.1 methods of treatment
180 patients with ischemic stroke were randomly divided into 6 groups of 30 persons each.
Control group 1: the aspirin enteric-coated tablets (German Bayer pharmaceutical company, batch number: national medicine standard J20171021) are orally taken 100 mg/time, 1 time/day respectively;
control group 2: intravenous drip edaravone injection (Nanjing pioneer pharmaceutical Co., ltd., lot number: national medicine standard H20031342), 10 mL/time, 1 time/day;
control group 3: a soft capsule of butylphthalide is orally taken (Shi Yao Jiu En Bipu pharmaceutical Co., ltd., batch number: national medicine standard H20050299), 0.2 g/time, 3 times/day.
Observation group: the medicine and the method of the embodiment 3 of the invention are added for treatment on the basis of the control group;
the treatment course is 8 weeks.
The diet should be light during the treatment period, and the food should not be spicy and irritated; all medications that might interfere with the study outcome are prohibited.
2.2 Observation index and scoring criteria
2.2.1 extent of neurological deficit
The neurological deficit degree scoring criteria are referenced to National Institutes of Health (NIHSS) scoring criteria.
2.2.2 daily life Activity ability
The daily living performance scoring criteria refers to the criteria of the pasteurization (BI) index rating scale scoring.
2.2.3 evaluation of the degree of disability
The evaluation of the degree of disability refers to the criteria of the modified rank scale (mRS) score.
2.2.4 quality of life assessment
Quality of life profiles recommended by the world health organization are employed.
2.2.5 integration of Chinese medical science syndromes
Is formulated by referring to the "apoplexy symptom classification quantification table" in the "Chinese medicine New medicine clinical research guidelines": 5 symptoms of dizziness, headache, limb numbness, limb weakness, shortness of breath and hypodynamia are taken as evaluation indexes. The symptoms are marked 0 point, the symptoms are lighter, the patients can bear 2 points, the symptoms are heavier, the life is marked 4 points, the symptoms are serious, and the patients cannot bear 6 points.
2.2.6 blood fat
TC, TG, HDL-C, LDL-C levels were determined.
2.1.7 adverse reactions
Observing the indexes of blood, urine and stool of patients, blood coagulation function, myocardial enzyme, liver and kidney functions, electrocardiogram and the like.
2.3 determination of efficacy
The neurological deficit scoring standard of the cerebral apoplexy patients is established by referring to the fourth cerebral vascular academy conference in China.
And (3) curing: symptoms and signs basically disappear, life can be self-managed, and the degree of disability is 0 level;
the effect is shown: the symptoms and signs are obviously improved, the neurological deficit score is reduced by more than or equal to 21 points, and the disease and disability degree is 1-3 grades;
the method is effective: the symptoms and the physical signs are obviously improved, and the score of the neurological deficit is reduced by 8-20 minutes;
invalidation: no obvious improvement of symptoms and signs before and after the administration, and less than 8 points of neurological deficit score.
Effective rate= (cure number + significant number + effective number)/total number of cases x 100%.
2.4 combined administration
Avoid using Chinese patent medicine for treating ischemic stroke. Can be used for treating other complications without affecting the evaluation of curative effect of the study drug
2.5 data processing
Statistical analysis was performed using the SPSS17.0 software package. The measurement data adopts t test, the counting data adopts chi-square test, and the grade data adopts Ridit test. P greater than 0.05 is no significant difference, P less than 0.05 is significant, and P less than 0.01 is extremely significant.
3. Results
3.1 Chinese medical symptomatic treatment
After treatment, the quality of life scores of the 6 groups and the Chinese medicine symptoms and signs are all obviously improved (P < 0.05) compared with the prior treatment. The observed group improved over the control group, and the differences were statistically significant (P < 0.05).
TABLE 3 Table 3
As can be seen from Table 3, the compound medicine of the present invention can be taken together on the basis of the control group, and the cure rate and the total effective rate can be significantly improved.
3. Clinical application
Some men, 52 years old, people in river basin, patient's hemiplegia, facial distortion, choking of drinking water. The clinical diagnosis of ischemic cerebral apoplexy is that after 1 treatment course of administration of the medicine according to the embodiment 1 of the invention, the hemiplegia at the affected part is relieved by drinking water and choking.
In order to treat ischemic cerebral apoplexy, a man, 43 years old, a person in the phoenix state, a patient with slurred speech, facial distortion and unsmooth eye deviation is clinically diagnosed, and the patient is treated by the medicine according to the embodiment 2 of the invention for 1 course of treatment, and the slurred speech and facial distortion are relieved.
Some women, 54 years old, people in the nan Ning market, patients with hemiplegia, slurred speech and headache. The clinical diagnosis of ischemic cerebral apoplexy is that after 1 course of treatment by administration of the drug according to example 3 of the present invention, the patients suffering from the symptoms of slurred speech and headache are relieved.
The above embodiments are merely illustrative of the principles of the present invention and its effectiveness, and are not intended to limit the invention. Modifications and variations may be made to the above-described embodiments by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is intended that all equivalent modifications and variations of the invention be covered by the claims, which are within the ordinary skill of the art, be within the spirit and scope of the present disclosure.
Claims (9)
1. The Zhuang medicine compound medicine for treating the acute stage of ischemic stroke is characterized by being prepared from the following raw materials in parts by weight: 30-40 parts of earthworm, 30-40 parts of suberect spatholobus stem and 30-40 parts of szechuan lovage rhizome.
2. The Zhuang medicine compound medicine for treating ischemic stroke in the acute stage of claim 1 is characterized by being prepared from the following raw materials in parts by weight: 30 parts of earthworm, 40 parts of suberect spatholobus stem and 30 parts of szechuan lovage rhizome.
3. The Zhuang medicine compound medicine for treating ischemic stroke acute stage according to claim 1 or 2, which is characterized in that: the application method comprises preparing the raw materials into medicinal liquid, taking 150mL, and taking 2 times after meals in the morning and evening.
4. The Zhuang medicine compound medicine for treating ischemic stroke in the acute phase of claim 3, which is characterized in that: 8 weeks is a treatment course.
5. A method for preparing a Zhuang medicine compound medicine for treating ischemic stroke acute stage according to claim 1 or 2, which is characterized by comprising the following steps:
(1) Soaking the raw materials in water;
(2) And after the soaking is finished, carrying out concentrated decoction to obtain the liquid medicine.
6. The method for preparing the Zhuang medicine compound medicine for treating ischemic stroke in the acute stage according to claim 5, which is characterized in that: in the step (1), the feed-liquid ratio is 1:6.
7. The method for preparing the Zhuang medicine compound medicine for treating ischemic stroke in the acute stage according to claim 5, which is characterized in that: in the step (1), the soaking time is 30-60 min.
8. The method for preparing the Zhuang medicine compound medicine for treating ischemic stroke in the acute stage according to claim 5, which is characterized in that: in the step (2), the decoction time is 30-40 min.
9. The method for preparing the Zhuang medicine compound medicine for treating ischemic stroke in the acute stage according to claim 5, which is characterized in that: in the step (2), the volume of the obtained liquid medicine is 150-170 mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211166878.3A CN115813972B (en) | 2022-09-23 | 2022-09-23 | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211166878.3A CN115813972B (en) | 2022-09-23 | 2022-09-23 | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115813972A CN115813972A (en) | 2023-03-21 |
| CN115813972B true CN115813972B (en) | 2023-09-12 |
Family
ID=85523914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211166878.3A Active CN115813972B (en) | 2022-09-23 | 2022-09-23 | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115813972B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857535A (en) * | 2006-03-06 | 2006-11-08 | 赵刚 | Medicine for treating cerebral infraction and its preparing method |
| CN1872180A (en) * | 2006-04-11 | 2006-12-06 | 广西玉林方特药业有限责任公司 | Medication of membranous milk vetch for activating blood and the channels, and preparation method |
| CN101152243A (en) * | 2006-09-26 | 2008-04-02 | 来柏龄 | Traditional Chinese medicine for treating apoplexy and technique of preparing the same |
-
2022
- 2022-09-23 CN CN202211166878.3A patent/CN115813972B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857535A (en) * | 2006-03-06 | 2006-11-08 | 赵刚 | Medicine for treating cerebral infraction and its preparing method |
| CN1872180A (en) * | 2006-04-11 | 2006-12-06 | 广西玉林方特药业有限责任公司 | Medication of membranous milk vetch for activating blood and the channels, and preparation method |
| CN101152243A (en) * | 2006-09-26 | 2008-04-02 | 来柏龄 | Traditional Chinese medicine for treating apoplexy and technique of preparing the same |
Non-Patent Citations (1)
| Title |
|---|
| 壮药双路通脑颗粒治疗缺血性中风临床观察;翟阳 等;中国民族医药杂志;第27卷(第10期);1-5 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115813972A (en) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN115414407B (en) | Zhuang medicine compound medicine for treating ischemic cerebral apoplexy and preparation method thereof | |
| CN104524106A (en) | Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN101411742B (en) | Capsule for freeing collateral vessels containing astragalus and leech | |
| CN115813972B (en) | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof | |
| CN104825905A (en) | Traditional Chinese medicine preparation for treating blood transfusion reaction and method for manufacturing traditional Chinese medicine preparation | |
| US20030143289A1 (en) | Herbal composition PHY828 and its use | |
| CN116999486B (en) | Zhuang medicine compound medicine for treating ischemic stroke convalescence and preparation method thereof | |
| CN105412621A (en) | Method for preparing pharmaceutical composition for treating hemorrhoids | |
| CN105106696A (en) | Traditional Chinese medicinal composition for treating chronic prostatitis | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN117379476A (en) | Traditional Chinese medicine composition for treating ischemic stroke convalescence and preparation method thereof | |
| CN104971236A (en) | Traditional Chinese medicine preparation for treating prosopalgia and preparation method thereof | |
| CN105560911A (en) | Traditional Chinese medicine for treating hypertension and preparation method thereof | |
| CN105434808A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN105031108A (en) | Medicine for treating chronic amyotrophic lateral sclerosis | |
| CN105343394A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN105250905A (en) | Traditional Chinese medicine composition for treating postpartum uterus subinvol ution and preparation method thereof | |
| CN103908502B (en) | A kind of Traditional Chinese medicine composition for the treatment of postpartum hemorrhage | |
| CN104666924A (en) | Medicine for treating liver-kidney yin deficiency type liver cirrhosis and preparation method of medicine | |
| CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia | |
| CN105012855A (en) | Medicine composition for treating stroke, as well as preparation method and application thereof | |
| CN118615344A (en) | Traditional Chinese medicine composition for treating chronic heart failure as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |